IASLC TTLC 2024 | Management options for patients with type II/III BRAF-mutated lung cancer

Rajwanth Veluswamy, MD, Icahn School Of Medicine At Mount Sinai, New York, NY, discusses treatment strategies for patients with type II or III BRAF-mutated lung cancer. Dimer specific inhibitors exist for these patients and Dr Veluswamy gives an overview of the disease biology behind the dimerization process. Immunotherapy additionally has a potential role, as these tumors are immunogenic. This interview took place at 2024 Targeted Therapies of Lung Cancer Meeting (TTLC 2024) in Santa Monica, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.